Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 221.00
Bid: 221.00
Ask: 222.50
Change: -1.50 (-0.67%)
Spread: 1.50 (0.679%)
Open: 222.50
High: 225.00
Low: 219.00
Prev. Close: 222.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PureTech narrows losses in 'most ambitious year yet'

Wed, 24th Apr 2019 09:17

(Sharecast News) - Biopharmaceutical company PureTech Health grew revenues and narrowed losses in its "most ambitious year yet".Revenues increased more than 700% to $20.7m due to an improved performance by affiliate Vedanta and a $4m grant, helping the group cut losses 9.8% to $104m for the 2018 calendar year.PureTech reported a consolidated cash balance of roughly $250.9m, with approximately $177.7m held at the parent company, while group cash and short-term investments came to $425m when including the cash and short-term investment balances held at independent affiliates.During the year, the London-listed firm received landmark FDA clearance for one of its own products, rolled out its internal pipeline for two validating pharmaceutical partnerships with Roche and Boehringer Ingelheim and saw five successful clinical trial readouts across its affiliate pipeline.Research and development costs increased 8% to $77.4m.Elsewhere, analysts at Jefferies reiterated their 'buy' rating and upped their target price on the group's "underappreciated" stock from 255p to 280p on Wednesday."After a newsflow heavy start to 2019, most notably the first regulatory approval for affiliate Gelesis, the main FY18 focus is $177m Parent Cash and extended runway to 1Q22E."Over the next six to twelve months, we foresee a number of key events for the portfolio companies that could ultimately crystallise value for PureTech."As of 0915 BST, PureTech shares had dropped 5.09% to 177p.
More News
9 Aug 2022 09:31

PureTech gets USD115 million from sale of Karuna Therapeutics shares

(Alliance News) - PureTech Health PLC on Tuesday announced it received USD115.4 million after selling a portion of its stake in Karuna Therapeutics Inc.

Read more
8 Aug 2022 17:06

LONDON MARKET CLOSE: Strong start to week as US inflation data looms

(Alliance News) - Stocks in London sprang into the new week after Friday's US jobs data lessened recession fears.

Read more
8 Aug 2022 16:21

IN BRIEF: PureTech shares jump on Karuna Therapeutics trial results

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says founded entity Karuna Therapeutics reports positive phase III trial results from Emergent-2 trial for KarXT in schizophrenia. KarXT, or xanomeline-trospium, met its primary endpoint in the trial, showing a significant 9.6 point reduction in Positive and Negative Syndrome Scale total score compared to a placebo. The PANSS scale measures the symptom severity of patients with schizophrenia. The trial also met key secondary endpoints, the firm says. Karuna plans to submit a new drug application with the US Food & Drug Administration in mid-2023.

Read more
1 Aug 2022 21:21

IN BRIEF: PureTech Health's Aliki starts phase three study for SDT-001

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Notes that founded entity Akili Interactive Labs Inc has start a pivotal phase three randomised, controlled study of SDT-001, a candidate designed to improve the measures of attention in children diagnosed with ADHD.

Read more
11 Jul 2022 19:15

TRADING UPDATES: BlueRock hit by extreme weather; Harbour drills well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
30 Jun 2022 21:50

IN BRIEF: PureTech Health begins pulmonary fibrosis study

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Begins late-stage clinical study of its wholly-owned candidate LYT-100, or deupirfenidone, in idiopathic pulmonary fibrosis. Will evaluate efficacy of two doses, as well as relative tolerability and efficacy with pirfenidone. IPF is a chronic condition causing progressive scarring of the lungs, which currently has a poor prognosis. Also advances LYT-200 programme through clinical development, and plans to begin leukemia study by the end of 2022.

Read more
28 Jun 2022 14:45

IN BRIEF: PureTech Health's founded firm Vedanta launches new facility

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Announces that its founded firm Entity Vedanta Biosciences Inc launches a new manufacturing facility. The facility will "provide clinical and commercial supply of oral therapies" for people infected with a diarrhoea-causing bacteria, firm says.

Read more
21 Jun 2022 14:24

IN BRIEF: PureTech Health's Gelesis wins USD15 million Plenity order

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Investee Gelesis Holdings Inc receives another USD15 million pre-order for its weight management aid product Plenity from its distribution partner, New-York based telehealth firm Ro. It brings the total orders from Ro to USD55 million, out of which USD45 million was ordered in the last 12 months, PureTech Health adds.

Read more
14 Jun 2022 16:54

IN BRIEF: PureTech achieves availability milestone for LYT-300 study

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Announces results from phase two study of LYT-100-COV on patients with post acute or long Covid with respiratory complications.

Read more
14 Jun 2022 07:33

PureTech reports 'Glyph' milestone, disappointing long Covid results

(Sharecast News) - PureTech Health said on Tuesday that it had met a milestone in proving its 'Glyph' therapeutic platform, while separately announcing disappointing results from a study into long Covid.

Read more
1 Jun 2022 18:21

TOP NEWS: Centrica warms up for FTSE 100 as Royal Mail sent packing

(Alliance News) - FTSE Russell confirmed on Wednesday that the following changes will take effect to its UK indices from the market open on Monday, June 20 after completing its quarterly review.

Read more
25 May 2022 10:18

Centrica and Johnson Matthey indicated to join FTSE 100, Asos in 250

(Alliance News) - British Gas-owner Centrica PLC and chemical firm Johnson Matthey PLC are set to return to the FTSE 100 index next month, replacing television broadcaster ITV PLC and postal operator Royal Mail PLC, according to indicative changes released by FTSE Russell on Tuesday.

Read more
5 May 2022 12:11

LONDON MARKET MIDDAY: Pound slips as BoE opts for quarter-point hike

(Alliance News) - Stock prices in London were higher, while the pound was flat, on Thursday, after the Bank of England as expected raised UK interest rates by a quarter percentage point.

Read more
5 May 2022 11:18

IN BRIEF: PureTech shares rise as unveils USD50 million share buyback

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Approves share buyback of up to USD50 million. Programme follows "follows consultation with shareholders and is consistent with PureTech's capital allocation strategy and stated approach to drive additional value for its shareholders," company says. PureTech says it had USD413.2 million of net cash and cash equivalents at March 31. Given size of balance sheet, PureTech is confident it can return capital to shareholders and also maintain "sufficient cash on hand to deliver" on strategic priorities.

Read more
5 May 2022 10:09

PureTech to buy back up to $50m of shares

(Sharecast News) - PureTech Health has announced a $50m share buyback programme, sending shares in the FTSE 250 biotech sharply higher.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.